<DOC>
	<DOCNO>NCT02963116</DOCNO>
	<brief_summary>This study randomize , open-label , 5-period , 5-treatment , single-dose , single-center , crossover study estimate effect AZD5718 pharmacokinetics ( PK ) rosuvastatin , assess relative bioavailability AZD5718 oral suspension v AZD5718 immediate release ( IR ) Tablet Formulation Food Effect AZD5718 Healthy Volunteers . The study perform single study center .</brief_summary>
	<brief_title>A Study Estimate Effect AZD5718 Pharmacokinetics ( What Does Body Does Drug ) Rosuvastatin Measure Relative Bioavailability ( Extent Which Drug Other Substance Becomes Available Body ) AZD5718 Oral Suspension v AZD5718 Immediate Release Tablet</brief_title>
	<detailed_description>The study comprise : - A Screening period maximum 28 day ; - Five treatment period subject resident morning day dose IMP ( Day -1 ) least 48 hour dose ; discharge morning Day 3 , - A Follow-up Visit within 7 10 day last administration IMPs . - There minimum 7 day washout treatment period . Each subject receive 5 treatment . The following treatment give : - Treatment A : 10 mg rosuvastatin tablet alone ( fast state ) - Treatment B : 10 mg rosuvastatin tablet + 200 mg AZD5718 IR tablet ( 2 x 100 mg tablet ) ( fast state ) - Treatment C : 200 mg AZD5718 IR tablet ( 2 x 100 mg tablet ) ( fast state ) - Treatment D : 200 mg AZD5718 oral suspension 50 mg/mL ( fast state ) - Treatment E : 200 mg AZD5718 IR tablet ( 2 x 100 mg tablet ) ( fed state ) Each subject involve study approximately 8 week .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>For inclusion study , subject fulfill follow criterion : 1 . Provision sign date , write informed consent prior study specific procedure . 2 . Healthy male and/or female subject ( non childbearing potential ) age 18 50 year ( inclusive ) suitable vein cannulation repeat venipuncture . 3 . Females must negative pregnancy test Screening Visit admission unit , must lactate must nonchildbearing potential , confirm Screening Visit fulfil one follow criterion 3.1 . Postmenopausal define amenorrhea least 12 month follow cessation exogenous hormonal treatment follicle stimulate hormone level postmenopausal range . 3.2 . Documentation irreversible surgical sterilization hysterectomy , bilateral ophorectomy bilateral salpingectomy exclude bilateral tubal ligation . 4 . Have body mass index ( BMI ) 18 30 kg/m2 inclusive weigh least 50 kg 100 kg , inclusive . 5 . Provision sign , write date informed consent optional genetic/biomarker research . If subject decline participate genetic component study , penalty loss benefit subject . The subject exclude aspect study . Subjects enter study follow exclusion criterion fulfil : 1 . History clinically significant disease disorder , opinion PI , may either put subject risk participation study , influence result subject 's ability participate study . 2 . History presence gastrointestinal , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug . 3 . Any clinically significant illness , medical/surgical procedure , trauma within 4 week first administration IMP . 4 . Any clinically significant abnormality clinical chemistry , hematology , urinalysis result , Screening Visit and/or admission study unit judge PI include : − Aminotransferase ( ALT ) &gt; upper limit normal ( ULN ) ; − Aspartate aminotransferase ( AST ) &gt; ULN ; − Total bilirubin ( TBL ) &gt; ULN ; − Gamma glutamyl transpeptidase ( GGT ) &gt; ULN . 5 . Any clinically significant abnormal finding vital sign Screening Visit and/or admission study unit , judge PI define follow : − Systolic BP ( SBP ) &lt; 90 mmHg ≥ 140 mmHg ; − Diastolic BP ( DBP ) &lt; 50 mmHg ≥ 90 mmHg ; − Pulse &lt; 45 &gt; 85 beat per minute ( bpm ) . 6 . Any clinically significant abnormality ( Screening Visit admission ) rhythm , conduction morphology rest ECG clinically significant abnormality 12lead ECG , consider investigator may interfere interpretation QTc interval change , include abnormal STTwave morphology , particularly protocol define primary lead leave ventricular hypertrophy . 7 . Any positive result screen serum hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody . 8 . Subjects myopathy . 9 . Has receive another new chemical entity ( define compound approve marketing ) within 3 month first administration IMP study . The period exclusion begin 3 month final dose 1 month last visit whichever long . Note : subject consent screen , randomize study previous phase I study , exclude . 10 . Plasma donation within 1 month Screening Visit blood donation/loss 500 mL 3 month prior Screening Visit . 11 . History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge PI history hypersensitivity drug similar chemical structure class AZD5718 and/or rosuvastatin . 12 . Current smoker smoke used nicotine product ( include ecigarettes ) within 3 month prior Screening Visit . 13 . Positive screen drug abuse cotinine Screening Visit admission study center positive screen alcohol admission study center . 14 . Excessive intake caffeine contain drink food ( e.g. , coffee , tea , chocolate ) , judge investigator . 15 . Use drug enzymeinducing property St John 's Wort within 3 week prior first administration IMP . 16 . Use prescribed nonprescribed medication include antacid , analgesic ( paracetamol/acetaminophen ) , herbal remedy , megadose vitamin ( intake 20 600 time recommended daily dose ) mineral 2 week prior first administration IMP long medication long halflife . Note : Hormonal replacement therapy allow female . 17 . Known suspected history alcohol drug abuse excessive intake alcohol judge PI . 18 . Involvement AstraZeneca , PAREXEL study site employee close relative . 19 . Subjects previously receive AZD5718 . 20 . Judgment PI subject participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction , requirement . 21 . Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order In addition , follow consider criterion exclusion optional genetic component study : 22 . Previous bone marrow transplant . 23 . Nonleukocyte deplete whole blood transfusion within 120 day date genetic sample collection previous bone marrow transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pharmacokinetics ( PK )</keyword>
	<keyword>Bioavailability ( BA )</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>